INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) will release its earnings data after the market closes on Thursday, October 31st. Analysts expect INmune Bio to post earnings of ($0.49) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

INmune Bio Trading Up 13.7 %

INMB stock opened at $6.17 on Tuesday. The firm has a market cap of $121.82 million, a PE ratio of -2.99 and a beta of 1.85. INmune Bio has a 1 year low of $4.78 and a 1 year high of $14.74. The company has a fifty day simple moving average of $5.71 and a 200 day simple moving average of $7.90.

Insider Buying and Selling at INmune Bio

In other INmune Bio news, CEO Raymond Joseph Tesi acquired 15,380 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the purchase, the chief executive officer now owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Raymond Joseph Tesi acquired 15,380 shares of the stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the purchase, the chief executive officer now owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David J. Moss bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average price of $5.29 per share, with a total value of $52,900.00. Following the completion of the purchase, the chief financial officer now owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 33,070 shares of company stock worth $200,087 over the last ninety days. Company insiders own 35.20% of the company’s stock.

Wall Street Analysts Forecast Growth

INMB has been the subject of several recent analyst reports. Raymond James started coverage on INmune Bio in a research note on Friday, September 27th. They set an “outperform” rating and a $18.00 price target for the company. Scotiabank assumed coverage on INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 target price for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 price target on the stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.